Home > HDAC & HDAC & HDAC & > Belinostat

Belinostat

贝利司他,NSC726630, PX-105684, PXD101,NSC 726630, PX 105684, PXD 101,NSC-726630, PX105684, PXD-101

Belinostat是一种新型的HDAC抑制剂，IC50为27 nM，对抵抗Cisplatin的肿瘤有效。

目录号
EY1661
EY1661
纯度
99.33%
99.33%
规格
10 mg
50 mg
原价
530
1680
售价
530
1680
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Belinostat (PXD101) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0.016-10 μM

  • 动物实验

    ≤40 mg/kg 腹腔注射

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Plumb JA, et al. Mol Cancer Ther, 2003, 2(8), 721-728.

    分子式
    C15H14N2O4S    		 分子量
    318.35    		 CAS号
    414864-00-9    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    65 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00865969 Peripheral T-cell Lymphoma Drug: PXD101 Spectrum Pharmaceuticals, Inc|Onxeo Phase 2 2008-12-01 2014-12-04
    NCT01317927 Solid Tumor|Hematological Malignancy Drug: Belinostat, Warfarin Spectrum Pharmaceuticals, Inc|Onxeo Phase 1 2010-12-01 2015-09-21
    NCT02679131 Relapsed/Refractory Solid Tumors/Hematological Malignancies Drug: Belinostat Spectrum Pharmaceuticals, Inc Phase 1 2016-03-01 2017-03-10
    NCT01583777 Advanced Cancer Drug: Belinostat Spectrum Pharmaceuticals, Inc Phase 1 2013-09-01 2016-07-20
    NCT00413075 Solid Tumor|Lymphoma Drug: oral belinostat Onxeo|Spectrum Pharmaceuticals, Inc Phase 1 2006-06-01 2015-07-07
    NCT02142530 Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma Drug: Carfilzomib|Drug: Belinostat Massachusetts General Hospital|National Comprehensive Cancer Network Phase 1 2014-10-01 2016-12-17
    NCT00274651 Cutaneous T-Cell Lymphoma|Peripheral T-Cell Lymphoma|Non-Hodgkin's Lymphoma Drug: belinostat Onxeo Phase 2 2006-01-01 2015-07-07
    NCT01090830 Non-Small-Cell Lung Carcinoma Drug: Belinostat, carboplatin, paclitaxel and bevacizumab Holy Cross Hospital, Florida Phase 1|Phase 2 2010-04-01 2013-03-19
    NCT00321594 Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer Drug: belinostat National Cancer Institute (NCI) Phase 1|Phase 2 2006-05-01 2013-01-30
    NCT00421889 Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Bladder Cancer Drug: belinostat|Drug: Paclitaxel|Drug: Carboplatin Onxeo Phase 1|Phase 2 2005-08-01 2015-07-07
    NCT02381548 Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Drug: Belinostat|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: WEE1 Inhibitor AZD1775 National Cancer Institute (NCI) Phase 1 2015-08-01 2017-02-03
    NCT01839097 Peripheral T-cell Lymphoma Drug: Belinostat|Drug: CHOP Spectrum Pharmaceuticals, Inc Phase 1 2013-05-01 2016-04-18
    NCT00301756 Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor|Recurrent Ovarian Carcinoma|Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor|Stage III Ovarian Cancer|Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor|Stage IV Ovarian Cancer Drug: Belinostat|Other: Laboratory Biomarker Analysis National Cancer Institute (NCI) Phase 2 2006-09-01 2016-10-20
    NCT00357162 de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Secondary Myelodysplastic Syndromes Drug: belinostat National Cancer Institute (NCI) Phase 2 2006-05-01 2014-05-02
    NCT02680795 Solid Tumors|Hematological Malignancies Drug: Belinostat IV|Drug: Belinostat IV|Drug: Belinostat Spectrum Pharmaceuticals, Inc Phase 1 2016-03-01 2017-03-10
    NCT00334789 Adult Solid Neoplasm Drug: Belinostat|Drug: Isotretinoin|Other: Pharmacological Study National Cancer Institute (NCI) Phase 1 2006-06-01 2016-12-26
    NCT02137759 Glioblastoma Multiforme of Brain Radiation: Standard Radiation Therapy|Drug: Standard Temozolomide|Drug: Belinostat Emory University|Johns Hopkins University|Spectrum Pharmaceuticals, Inc|National Cancer Institute (NCI) Phase 2 2014-05-01 2016-09-22
    NCT01188707 Non Small Cell Lung Cancer Drug: Belinostat and Erlotinib Herlev Hospital|Copenhagen University Hospital at Herlev|Bispebjerg Hospital|Onxeo|Roche Pharma AG Phase 1|Phase 2 2010-12-01 2011-08-03
    NCT01273155 Neoplasms|Lymphomas Drug: Belinostat National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1 2010-12-22 2017-03-08
    NCT01310244 Stage IV Non-small Cell Lung Cancer Drug: Belinostat, Carboplatin, Paclitaxel Spectrum Pharmaceuticals, Inc|Onxeo Phase 1|Phase 2 2010-12-01 2015-09-21
    NCT00878800 Dose Escalation: Solid Tumors|MTD: Soft Tissue Sarcomas Drug: PXD101|Drug: Doxorubicin Onxeo|Spectrum Pharmaceuticals, Inc Phase 1|Phase 2 2006-12-01 2015-07-07

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：